Soticlestat as Adjunctive Therapy in Dravet Syndrome

Phase 3, randomised, double-blind trial in Dravet syndrome comparing Placebo with Soticlestat (2 arms). Primary endpoints: Percent Change From Baseline in Convulsive Seizure Frequency Per 28 Days During the Full Treatment Period at 16 weeks and Percent Change From Baseline in Convulsive Seizure Frequency Per 28 Days During the Maintenance Period at 16 weeks. Started Oct 2021; status: completed.